



Correction to: Additional value of metabolic parameters to PET/CT-based radiomics nomogram in predicting lymphovascular invasion and outcome in lung adenocarcinoma

Pei Nie¹ · Guangjie Yang² · Ning Wang³ · Lei Yan² · Wenjie Miao² · Yanli Duan² · Yanli Wang⁴ · Aidi Gong² · Yujun Zhao² · Jie Wu⁵ · Chuantao Zhang⁶ · Maolong Wang⁷ · Jingjing Cui⁸ · Mingming Yu² · Dacheng Li² · Yanqin Sun² · Yangyang Wang² · Zhengguang Wang²

Published online: 28 July 2020

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to: European Journal of Nuclear Medicine and Molecular Imaging.

<https://doi.org/10.1007/s00259-020-04747-5>

Figures 1 and 4 are incorrect in the original manuscript. The correct Figs. 1 and 4 are shown below.

Also, In Table 4, “EGFR mutation (\pm ND)” is not correct, it should be “EGFR mutation (+/- ND)”, because “+” and “-” means positive and negative, respectively. The correct Table 4 is shown below:

The original article has been corrected.

This article is part of the Topical Collection on Erratum

The online version of the original article can be found at <https://doi.org/10.1007/s00259-020-04747-5>

✉ Zhengguang Wang
doctorwzg2002@hotmail.com

¹ Department of Radiology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, China

² Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, Shandong, China

³ Department of Radiology, Shandong Provincial Hospital, No. 324, Jingwu Road, Jinan, Shandong, China

⁴ PET-CT Center, Qingdao Central Hospital, No. 127 Siliu South Road, Qingdao, Shandong, China

⁵ Department of Pathology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, China

⁶ Department of Oncology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, China

⁷ Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, China

⁸ Huiying Medical Technology Co., Ltd, No. 66 Xixiaokou Road, Beijing, China




Fig. 1 Construction of radiomics signatures (RSs). **a, b** CT ROI segmentation. **c, d** PET ROI segmentation. **e, f, g** Two-dimensional (2D) CT, three-dimensional (3D) CT, and PET features selection using the least absolute shrinkage and selection operator (LASSO)

regularization. **h, i, j** The selected 8 2D CT features, 8 3D CT features, 10 PET features and their coefficients. **k, l, m** The 2D CT radiomics scores (Rad-scores), 3D CT Rad-scores, and PET Rad-scores for each patient in the training and test sets




Fig. 4 Progression-free survival (PFS) curves according to pathologic LVI status (a) and CT-RNWS-predicted LVI status (b) in the 244 CT-RNWS-predicted cohort. c Forest plot of independent predictors of PFS with a multivariate Cox regression model. LVI, lymphovascular invasion;

RNWS, radiomics nomogram with SUVmax; HR, hazard ratio; CI, confidence interval; CA125, carbohydrate antigen 125; CEA, carcinoembryonic antigen; NSE, neuron-specific enolase

Table 4 The pathologic and therapeutic factors

Factors	Pathology LVI+ (n = 87)	Pathology LVI- (n = 185)
Stage		
I	25	134
II	20	18
III	37	26
IV	5	7
Histological subtype (Low risk/ High risk)	18/69	121/64
EGFR mutation (+/-/ ND)	29/25/33	88/48/49
Surgical approach (Lobectomy/ Sublobectomy)	80/7	169/16
Treatment after surgery		
Chemotherapy	31	32
Targeted therapy	4	16
Chemotherapy and targeted therapy	11	8
No treatment	41	129

LVI (lymphovascular invasion); EGFR (epidermal growth factor receptor); ND (not detected).